Collaborations & Alliances
Related Searches:
Filter by:
646 - 660 of 1095 results
January 13, 2010
Novo Nordisk has initiated its first Phase I trial with a long-acting oral GLP-1 analogue (NN9924), triggering a $2 million milestone payment to development partner Emisphere Technologies.
Read More »
January 12, 2010
Microbix Biosystems and Therapure Biopharma have signed a partnership agreement to manufacture and market water-based products to the pharmaceutical, biotechnology and other industries.
Read More »
January 11, 2010
WuXi AppTec has entered into a partnership with Qiagen to provide an integrated solution for molecular biomarker development, validation and personalized healthcare targets to their respective clients.
Read More »
January 7, 2010
Pfizer and Strides Arcolab entered a new collaboration under which Pfizer will commercialize off-patent sterile injectable and oral products in the U.S. through its Established Products Business Unit.
Read More »
January 6, 2010
Alnylam Pharmaceuticals received a milestone payment from its partner Roche for the initiation of pre-IND studies for an RNAi therapeutics product candidate.
Read More »
January 5, 2010
Laureate Pharma and Selexis SA, a Swiss-based contract developer of high performance production cell lines, will continue their collaboration via a joint marketing agreement.
Read More »
December 28, 2009
Merck, through an affiliate, has decided to discontinue development of MK-1903 and ended its research collaboration with Arena.
Read More »
December 22, 2009
GSK buys into antibody-drug conjugate program, with max. payout of $390 million.
Read More »
December 22, 2009
AZ has acquired Biovitrum's leptin modulator program.
Read More »
December 22, 2009
Zymo will market Recothrom in all regions, except Canada.
Read More »
December 18, 2009
Astellas pays $40 million for Phase II AML treatment.
Read More »
December 17, 2009
GSK pays $10 million alliance after favorable candidate.
Read More »
December 16, 2009
Companies will combine on diabetes drug in Middle Kingdom
Read More »
December 15, 2009
Seattle Genetics and Millennium have entered into a development and commercialization agreement for lymphoma treatment brentuximab vedotin.
Read More »
December 11, 2009
Genentech has terminated its collaboration with Seattle Genetics for dacetuzumab.
Read More »
646 - 660 of 1095 results
